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Within the human intestinal tract, dietary, microbial- and host-derived compounds are
used as signals by many pathogenic organisms, including Clostridioides difficile.
Trehalose has been reported to enhance virulence of certain C. difficile ribotypes;
however, such variants are widespread and not correlated with clinical outcomes for
patients suffering from C. difficile infection (CDI). Here, we make preliminary observations
on how trehalose supplementation affects the microbiota in an in vitro model and show
that trehalose-induced changes can reduce the outgrowth of C. difficile, preventing
simulated CDI. Three clinically reflective human gut models simulated the effects of
sugar (trehalose or glucose) or saline ingestion on the microbiota. Models were instilled
with sugar or saline and further exposed to C. difficile spores. The recovery of the
microbiota following antibiotic treatment and CDI induction was monitored in each model.
The human microbiota remodelled to utilise the bioavailable trehalose. Clindamycin
induction caused simulated CDI in models supplemented with either glucose or saline;
however, trehalose supplementation did not result in CDI, although limited spore
germination did occur. The absence of CDI in trehalose model was associated with
enhanced abundances of Finegoldia, Faecalibacterium and Oscillospira, and reduced
abundances of Klebsiella and Clostridium spp., compared with the other models.
Functional analysis of the microbiota in the trehalose model revealed differences in the
metabolic pathways, such as amino acid metabolism, which could be attributed to
prevention of CDI. Our data show that trehalose supplementation remodelled the
microbiota, which prevented simulated CDI, potentially due to enhanced recovery of
nutritionally competitive microbiota against C. difficile.
Keywords: Clostridium difficile, trehalose, human microbiota, microbial competition, in vitro gut modelgy | www.frontiersin.org July 2021 | Volume 11 | Article 6709351
Buckley et al. Effect of Sugars on the MicrobiotaINTRODUCTION
Trehalose is a disaccharide sugar consisting of two a-glucose
monomers linked via 1,1-glycosidic bond and is present in a wide
variety of organisms, such as bacteria, yeast, insects, plants, and
animals. The structure of trehalose makes it highly resistant to
acid hydrolysis, it is used as a high energy storage molecule for
insect flight, and also as a dehydration or cryo-protectant in
some microorganisms, plants and animals (Elbein et al., 2003).
This sugar is naturally found in foods, such as mushrooms and
honey, but following the discovery of a cost-effective method of
large-scale production (Maruta et al., 1995) and regulatory
approval as a food additive, trehalose is now added to a range
of processed food products (cereals, pasta, sweets and ice cream),
cosmetics and some medicines (Food Standards Australia New
Zealand (FSANZ), 2003; Pinto-bonilla et al., 2015). In the human
digestive tract, trehalose is metabolised by host-produced
trehalase enzymes located at the intestinal brush border, as
well as microbial-produced trehalases. Many intestinal bacteria
and yeasts produce trehalase enzymes, including Bacillus spp.,
Escherichia coli, Blautia spp., Lactobacillaceae and the
nosocomial pathogen Clostridioides difficile (Arguelles, 2000;
Bateman et al., 2017; Collins et al., 2018a).
C. difficile is the leading cause of antibiotic-associated
diarrhoea (Rupnik et al., 2009), where antibiotic-induced
microbiota depletion provides favourable conditions for the
germination of C. difficile spores, which proliferate and
produce toxins that cause disease. These toxins (TcdA and
TcdB) are responsible for a range of symptoms from mild, self-
limiting diarrhoea to pseudomembranous colitis, colonic
perforation and death (Rupnik et al., 2009). Antibiotic
treatment can fail to resolve the infection, with up to 30% of
cases recurring after primary treatment (Marsh et al., 2012).
Depletion of the intestinal microbiota means C. difficile is
exposed to several compounds normally metabolised by the
healthy microbiota; some of these are used as either molecular
signals or as a source of energy, such as the primary bile acids
cholate and succinate (Sorg and Sonenshein, 2008; Ferreyra et al.,
2014). Collins et al. showed that ingested trehalose enhanced C.
difficile virulence (Collins et al., 2018a). Additionally, C. difficile
ribotypes (RT) typically associated with CDI outbreaks,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2e.g. RT027 or RT017, have a mutated treR repressor gene,
which overexpresses the trehalose metabolism gene (treA),
whilst other ribotypes, i.e. RT078, show enhanced trehalose
uptake, through the presence of a novel phosphotransferase
(PTS) system transporter (Collins et al., 2018b). However, it is
reported that such variants are common in C. difficile isolates and
comparison of the clinical outcome of CDI patients to trehalose
metabolic genotype of the isolated strain found no correlation
between 30-day mortality and the trehalose metabolic genotype
(Eyre et al., 2019). Moreover, Saund et al. found no statistically
significant association between the presence of trehalose
utilisation variants in infecting C. difficile strains and the
development of severe infection outcome (Saund et al., 2020).
Using a previously successful in vitro model developed to
simulate human CDI in the large intestine (Freeman et al., 2003),
we measured microbial compositional changes following
trehalose and glucose supplementation and the effect of sugar
supplementation on C. difficile growth kinetics after antibiotic
disruption of the microbiota. A schematic timeline of our
experimental design is shown in Figure 1. Enumeration of C.
difficile from the in vitro gut model when predicting treatment
and antibiotic induction outcomes have been shown to be
clinically reflective, and in some cases, more accurate than
results from animal models. Antibiotics with a high propensity
to induce CDI in patients also induce simulated CDI within the
gut model (Freeman et al., 2003; Saxton et al., 2009; Crowther
et al., 2013; Chilton et al., 2014). Conversely, antibiotics with a
lower in vitro propensity to induce simulated CDI are now
recognised to have low CDI risk (Baines et al., 2005; Saxton
et al., 2009). Crucially, the gut model has been used for in vitro
evaluation of drug efficacy against simulated CDI at various
stages of pre-clinical and clinical drug development. For
fidaxomicin, data from animal and in vitro models correlated
well with Phase III clinical trials (Swanson et al., 1991; Crook
et al., 2012; Chilton et al., 2014), whereas for the toxin binding
agent, tolevamer, results from the triple-stage gut model
predicted clinical failure of this agent at Phase III, while
animal model data did not (Kurtz et al., 2001; Baines et al.,
2009; Johnson et al., 2014). Following gut model investigations of
cadazolid (Chilton et al., 2014), surotomycin (Chilton et al.,
2014) and SMT19969 (Baines et al., 2015) for treatment of CDI,FIGURE 1 | Schematic timeline of the in vitro triple vessel chemostat gut model and experimental design for each model. C. difficile spores (black lines) were instilled
and commencement of sugar regimen [either trehalose (T), glucose (G) or saline (S) (green arrow)] before addition of antibiotics (blue arrow). Microbial populations
were monitored post antibiotic for recovery and induction of CDI. Numbers in italicise brackets denotes the day that samples for DNA extraction were taken.July 2021 | Volume 11 | Article 670935
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publication detailing efficacy of extended duration fidaxomicin
therapy (Chilton et al., 2015) led to the current Phase IIIB/IV
trial investigating such dosing regimens in the clinic . In fact, data
from gut model studies (Baines et al., 2005; Chilton et al., 2012;
Baines et al., 2013) have informed UK national antibiotic
prescribing guidelines (Public Health England, 2016). Using
this in vitro model, we investigated the effects of trehalose on
the colonic microbiota and progression of simulated CDI.MATERIALS AND METHODS
Gut Model Set Up
Three triple-stage in vitro gut models were run in parallel as
previously described (Moura et al., 2019). Briefly, each model
consists of three chemostat vessels arranged in a weir cascade
system, top-fed with a complex growth medium at a controlled
rate (D=0.015 h-1). All three vessels were continuously stirred,
anaerobically maintained at 37°C and regulated to reflect in vivo
intestinal conditions. The three vessels are representative of the
colon, reflecting increased pH and decreased nutrient availability
from the proximal colon (vessel 1, pH 5.5 ± 0.2), through the
medial colon (vessel 2, pH 6.2 ± 0.2) to the distal colon (vessel 3,
pH 6.8 ± 0.2). A faecal slurry (10% w/v) was made by diluting
pooled human faeces from healthy elderly volunteers (n =
five; >59 years of age; CDI negative; no prior three-month
history of antibiotic exposure) with pre-reduced PBS. Donors
over the age of 59 were used to represent the at-risk group for
developing CDI. This slurry, approximately 500 ml per model,
was used to seed the vessels for each gut model at the start of
the experiment.
Experimental Timeline
For each model, the microbial populations were allowed to
equilibrate for two weeks to reach ‘steady state’ without
intervention; consistent stable microbial recoveries over 5 days
from all microbial populations tested was used to determine
‘steady state’. A single one ml aliquot of C. difficile RT027 strain
210 spores (approximately 107 cfu/ml) were inoculated into
vessel 1 of each model and sugar supplementation commenced
(Figure 1). Models were dosed with either glucose (n=1 model;
model G; 1120 mM dosed thrice daily for 35 days), trehalose
(n=1 model; model T; 560 mM thrice daily for 35 days), or
phosphate buffered saline (n=1 model; model S; thrice daily for
35 days) (Figure 1 – green arrow). The dosing regimens were
inoculated in vessel 1, and sufficient to achieve final trehalose
and glucose concentrations in vessel 1 of each model of 10 mM
and 20 mM, respectively, i.e. consistent with levels observed in
humans consuming trehalose (Abbott and Chen; Food
Standards Australia New Zealand (FSANZ), 2003). A second
dose of C. difficile strain 210 spores were inoculated as
previously described, followed by a clindamycin regimen (33.9
mg/l four times daily for seven days) to induce simulated CDI
(Chilton et al., 2014). The first C. difficile spore dose was added
to ensure that the microbial populations within the model hadFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3equilibrated and were able to prevent C. difficile spore
germination; an effect called colonisation resistance. This
ensured that the effects of any downstream manipulations of
the microbiota were due to those manipulations rather than
incomplete colonisation resistance.
Preparation of Ribotype-027 C. difficile
Strain 210 Spores
Similar to other strains of ribotype-027, C. difficile 210 strain has
a mutated treR repressor gene, as reported in (Collins et al.,
2018a). C. difficile spores for gut model inoculation were
prepared as previously described (Buckley et al., 2011). Briefly,
C. difficile 210 was grown in BHI broth anaerobically at 37°C for
six days and removed from the incubator and incubated
aerobically at room temperature overnight to further induce
sporulation. Growth was harvested by centrifugation and
incubated with PBS supplemented with 10 mg/ml lysozyme at
37°C overnight. Samples were separated using a sucrose gradient
and spores were treated with PBS supplemented with 20 ng/ml
protease K and 200 nM EDTA. Spores were separated using a
sucrose gradient and washed with PBS twice before a final
resuspension in 30 ml. These were enumerated and diluted to
approximately 1x107 spores/ml for use in the models.
Bacterial Enumeration Using
Selective Agars
Vessel 3 ofmodels T, S andGwas sampled daily for culture profiling
of total bacteria, lactose-fermenting Enterobacteriaceae, Clostridium
spp., Lactobacillus spp., Bifidobacterium spp., Enterococcus spp., and
Bacteroides spp., and C. difficile populations as described in
Supplementary Methods and Supplementary Table 4. Colonies
from these plates were identified to a species level by MALDI-
TOF analysis.
Cytotoxin Assay
A VERO cell-based assay was used to approximate the level of
toxin present in the gut model. This assay is a semi-quantitative
measure of toxin activity within the gut models as many factors
can affect the action of the toxin, e.g. protein levels, which were not
normalised across each time point & sample. Samples from vessels
1, 2 & 3 were centrifuged and stored at 4°C before testing. Samples
were serially diluted 1:10 and co-incubated with a confluent
monolayer of VERO cells and incubated for 48 hr at 37°C, 5%
CO2. Toxin positivity was indicated by >50% cell rounding, while
the confluent cell monolayer was unaffected in toxin negative
samples. Presence of C. difficile toxin was confirmed by
neutralisation of neat sample with C. sordellii antitoxin.
Antibiotic Bioassay
The concentration of clindamycin in each vessel was determined
by bioassays as previously described (Chilton et al., 2014).
Briefly, indicator organism Kocuria rhizophila (ATCC 9341)
was inoculated into Wilkins-Chalgren agar and aseptically
transferred into 245 x 245 mm agar plates. These plates were
allowed to set, and nine mm wells were made using a cork borer.
A calibration series of the antibiotic was added to each plate andJuly 2021 | Volume 11 | Article 670935
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aerobically at 37°C. Zone diameters were measured using
callipers and concentration curves plotted from squared zone
diameters and unknown concentrations from vessel
supernatants determined. Assays were performed in triplicate.
Trehalose and Glucose Concentration
Daily gut model samples from all vessels of each model were
assessed by ion chromatography for trehalose and glucose
concentrations. Samples were tested in a blind fashion. Gut
model samples were centrifuged at 15,000 rpm for 10 mins, and
the supernatant was further centrifuged usingmillipore centrifugal
filter units with a 50 kDa and 3 kDa cut off to remove proteins and
bigger macromolecules. Samples were diluted 1:10 in ultrapure
water and analysed by ion chromatography. 25 µl of sample was
injected on a Dionex ICS-5000 plus ion chromatography system
(Thermo fisher Scientific, USA). The separation was carried out on
a Dionex CarboPac PA1 Analytical Column (4 x 250 mm) with a
Dionex CarboPac PA1 Guard Column (4 x 50 mm). The column
temperature was set at 30°C. Elution was performed using three
elutants; A: ultrapure water, B: 300 mM sodium hydroxide and C:
300 mM sodium hydroxide with 1500 mM sodium acetate, with a
flow rate of one ml/min. The linear gradient condition is shown in
Supplementary Table 5. The analytes were detected by using an
electrochemical detector.
DNA Extraction, Bacterial 16S rRNA
Library Preparation and Sequencing
The bacterial 16S rRNA sampling regimen from vessel 3 of all
three models are shown in Figure 1. Samples were taken prior to
the first sugar dose, first clindamycin dose, in the middle of
clindamycin dosing, 2 days after last clindamycin dose, i.e. after
washout of clindamycin from the system, and weekly thereafter.
Four one ml aliquots, representing four technical replicates, from
vessel 3 of each model were pelleted, the supernatant discarded,
and the DNA extracted from the pellet using FastDNA™ SPIN
kit for soil (MP Biomedicals™) following manufacturers’
instructions. DNA was stored at -80°C until used for downstream
analysis. DNA quality and double-stranded quantities were
determined using the picogreeen absorption method. Bacterial
16S rRNA V4 fragments were PCR amplified using NEBNext Q5
Hot Start HiFi PCR master mix (NEB, U.K.) with universal 16S
rRNA V4 primers [564F (TCGTCGGCAGCGTCAGAT
GTGTATA>AGAGACAG-AYTGGGYDTAAAGNG) and 806R
(GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-
TACNVGGGTATCTAATCC)] with Illumina adaptor sequence
overhangs included using the PCR cycle [denaturation (95°C x3
min for 1 cycle), amplification (95°Cx30 sec, 50°Cx30 sec, 72°Cx30
sec, for 28 cycles) and final elongation (72°C x5 min for 1 cycle)].
PCR products were cleaned using AxyPrep Magnetic beads
(Axygen, U.K.) and the 16S rRNA fragments checked using gel
electrophoresis on an Agilent 2200 TapeStation system (Agilent
Genomics, U.K.) before running a PCR for addition of the index
sequences [denaturation (95°C x3 min for 1 cycle), amplification
(95°C x30 sec, 55°C x30 sec, 72°C x30 sec, for 8 cycles) and final
elongation (72°C x5min for 1 cycle)]. The fragments were cleaned,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4quantified (as before), normalised and samples sequenced using
MiSeq sequencer (Illumina) with 250 bp paired-end reads. Library
preparation and sequencing was done at the University of Leeds
sequencing facility.
Taxonomic Analysis on 16S rRNA
Gene Sequences
Demultiplexed FASTQ files of 16S rRNA sequences were
trimmed of adapter sequences using cutadapt (Martin, 2011),
and samples were filtered based on the number of reads across all
samples to provide similar coverage. We followed the standard
operating procedure from the MOTHUR package (v.1.41.3)
(Schloss et al., 2009). The paired reads were joined together
and assembled into the contigs, and quality controlled based on
the parameters such as maxambig=0, minlength=177 and
maxlength=237. Unique sequences were aligned against a
tailor-made reference generated from SILVA SEED database
(version 132) and further filtered according to their start and
end positions in the alignments. In order to reduce the possible
redundancy to a minimum, the identical and very similar
sequences (within 2bp mismatch) were merged. The chimeric
sequences were discarded based on the built-in VSEARCH
method (Rognes et al., 2016). OTUs (operational taxonomic
units) were identified by clustering (0.5 UniFrac distance) the
sequences and were assigned the consensus taxonomy
information with label=0.03. Low abundant reads (<50 reads
per sample, which accounted for <0.04% of the total reads) were
removed before further analysis; however, this precludes the
contribution of low abundance taxonomic families in our
analysis whilst ensuring accuracy from sequencing artifact.
Taxonomic analysis is represented as mean percent abundance
from four technical replicates. To determine if a microbial
community was differentially abundant between the technical
replicates of the three models on a given day a differential
abundance analysis was performed and a microbial community
was considered significantly different when the false discovery
rate (FDR) p value was ≤ 0.01 and a -1.5 ≤ Log2 fold change ≥ 1.5
of the populations in model T in comparison with models G and
S was observed. The same cut off values were used to determine
the difference in abundance of the microbial populations of the
slurry compared to the models T, G, and S at day 14. For the
calculations of bacterial diversity, Shannon diversity index was
computed for all samples and the distance matrix based on
thetayc approach was used for Principal Coordinates (PCoA)
analysis and visualization for each group of samples, based on
four technical replicates. A Mann-Whitney U test was performed
to determine statistical significance between the pre-clindamycin
Shannon diversity index reference and the other timepoints for
each model.
Functional Analysis of the Microbiota
All samples collected from model T throughout the experiment
(time points shown in Figure 1) and samples from model S and
G on day 38 (1-week post clindamycin), were selected for
shotgun metagenome sequencing. Four technical replicates
were investigated for each time point. Extracted DNA wasJuly 2021 | Volume 11 | Article 670935
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focused ultrasonicator (Covaris, U.K.). NEBNext Ultra DNA
Library prep kit for Illumina was used for adaptor ligation and
to PCR enrichment following manufacturer’s instructions.
Libraries were sequenced using Illumina HiSeq 3000 sequencer
(University of Leeds). FASTX-Toolkit (version 0.0.13) was used
to trim the first 10 bp from the sequence reads. MEGAN UE
(ultimate edition v6.18.0) was used to functionally annotate and
compare the sequencing reads using inbuilt programme tools
(Huson et al., 2016). Briefly, paired-end reads were aligned on to
NCBI-nr database (version 14.12.19; nr.gr size: 52.5 Gb) using
DIAMOND (Buchfink et al., 2014) and Meganizer was used to
perform functional analysis of the DIAMOND input files using
either an up-to-date representation of KEGG or Pfam-A
database (version 32). KEGG orthologous groups (Ko groups)
were mapped to enzymes that appear in metabolic pathways.
Functional analysis using KEGG assigned 39-43% of the total
reads to a Ko group. An abundance table of functional categories
for each sample was generated and a differential proportion-
based abundance analysis, based on z test (Kal et al., 1999), was
performed. A functional annotation was considered significantly
different when the false discovery rate (FDR) p value was ≤ 0.05
and a -1.5 ≤ Log2 fold change ≥ 1.5 of the populations, based on
z-score, in model T in comparison with models G and S.
Variations in Ko groups (metabolic pathways and surface
components) were considered significant when the fold-change
of at least 80% of the genetic components in that pathway were
either more or less abundant (as described above). The
abundance of trehalase-specific Pfam terms, trehalase (clan
0059) and trehalose phosphatase (clan 0137), throughout all
timepoints of model T were compared, and fold change
abundance calculated.
Taxonomic Profiling of Whole
Genome Sequences
Taxonomic profiling from the whole genome paired sequences
generated above was performed using CLC GenomicsWorkbench
(version 12.0.3), with the CLC Microbial Genomics Module
(version 4.8). Trimmed sequences were imported into the CLC
software and each sequence read individually mapped to the fully
curated (as of June 2019) microbial reference database, based on
selected references from GenBank and RefSeq, using the default
settings in the Taxonomic Profiling tool. Abundance tables were
merged, and the Differential Abundance Analysis tool used to
determine the abundance differential in taxa, compared to model
T, based on a Log2 fold-change <-2 or >2 and a Wald test false
discovery rate (FDR) p value <0.001.RESULTS
Reconstitution of the Human Microbiota
in the Gut Model
Each triple-staged gut model is seeded with a faecal slurry made
using the pooled faecal matter from five healthy donors to
capture a diverse representation of the human microbialFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 5populations (Figure 1). Firstly, we sought to characterise the
microbial diversity captured from this slurry in each gut model.
The donors used in this study showed distinct microbial profiles
to each other (Supplementary Table 1), except for donors E and
C, which clustered together, indicating similar microbiota
profiles. Similarly, the faecal slurry used clustered distinctly
from each donor but nested amongst the donors, suggesting
the slurry contains the overall diversity from the donors; indeed,
the slurry contained 36 bacterial families, more than each
individual donor (Figure 2A). As determined by bacterial
taxonomic analysis by 16S rRNA sequencing, the slurry was
found to contain bacterial family members that were unique to a
single donor, for example Eubacteriaceae and Muribaculaceae
were only present in Donor C and the slurry (Supplementary
Table 1). Once the microbial populations had stabilised in the
three models, the predominant bacterial families were
represented at similar levels to the slurry (Figures 2B, C),
although some differences were observed. Compared with the
faecal slurry, Bifidobacteriaceae abundance increased and
Clostridiaceae abundance decreased in all models at steady
state, whereas Coriobacteriaceae showed increased abundance
in models G and S and Enterococcaceae abundance increased in
model T (Figure 2C). However, Bifidobacteriaceae did decrease
in all models one week later, which was confirmed by
direct enumeration.
The Changing Bioavailability of Trehalose
The trehalose dosing regimen in model T was designed to mimic
the average trehalose content from meals consumed thrice daily
by an adult, which can vary amongst adults and different countries
(Abbott and Chen; Food Standards Australia New Zealand
(FSANZ), 2003). Trehalose was undetected in the saline (control)
model S and was only detected periodically in vessel 1 (proximal
colon) of the model G dosed with glucose (0.01 mM), whereas
trehalose supplementation in model T increased detectable
trehalose concentrations, peaking at 8.1 mM in vessel 1 of model
T prior to addition of antibiotics (Figure 3). Trehalose was largely
undetectable in vessels 2 (medial colon, pH 6.2 ± 0.2) and 3 (distal
colon, pH 6.8 ± 0.2) of each model, although trehalose was observed
in vessel 2 up to three days after commencing dosing, peaking at 4.3
mM (Supplementary Table 2). As trehalose can be catabolised into
two glucose molecules, model G was dosed with glucose at double
the concentration of trehalose to determine if any effects of trehalose
on the microbial populations was not due to the increased glucose
availability (Figure 3A). Prior to antibiotic dosing, commencement
of the glucose dosing regimen was associated with a peak glucose
concentration of 16.1 mM in model G, compared with 0.1 mM and
0.007 mM in models T and S, respectively.
Addition of clindamycin induced microbial dysbiosis in model
T, which correlated with increased luminal concentrations of
trehalose in all vessels (Supplementary Table 2); peak trehalose
detection in vessels 1, 2 and 3 were 13.3, 6.7 and 2.5 mM,
respectively (Figure 3). However, luminal concentrations of
trehalose reduced to undetectable levels in vessels 2 and 3, and
to approximately 2.1 mM in vessel 1, on the last day of
clindamycin instillation (day 31). A similar pattern of increased
trehalose bioavailability during clindamycin instillation, albeit atJuly 2021 | Volume 11 | Article 670935
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(vessel 1-3), which, although were not dosed with trehalose
throughout the experiment, had trehalose in the growth media.
During clindamycin instillation, we detected greater bioavailability
of glucose in all models at day 26, particularly in vessel 1
(Figure 3). Model G had the highest concentration, peaking at
28.3 mM and concentrations in models T and S peaked at 1.6 and
1.8, respectively. The initial reduction inmicrobial diversity caused
by clindamycin, and the increased trehalose bioavailability,
resulted in an increased abundance of microbial genomes
harbouring Pfam domains for trehalose metabolism [trehalase
(clan 0059) and trehalose phosphatase (clan 0137)]; these domains
increased 4.6- and 4.4-fold, respectively, compared with the
abundance of these domains pre-trehalose levels (Table 1). One
week after clindamycin, the abundance of these Pfam domains
reduced to levels similar to pre-clindamycin.
Remodelling of the Microbiota in
Response to Trehalose
Changes in the bacterial composition of the three models (T, G,
and S) were monitored by 16S rRNA sequencing and taxonomic
analysis (timepoints shown in Figure 1) and direct enumeration of
selected bacterial populations (daily monitoring), to determine
how trehalose dosing affected the gut microbiota, compared to
glucose or saline. Prior to clindamycin exposure, the microbial
populations largely remained stable in the control (saline dosed)
model (Figure 4), whilst trehalose exposure in model T was
specifically associated with an increase in abundance of
Bacteroides uniformis to almost 3% of the total bacterialFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 6populations, identified by shotgun metagenomic sequencing.
This increase was confirmed by selective enumeration of
Bacteroides spp. and species identification by MALDI-TOF
analysis. Similar abundance increases were observed in other
microbial populations specifically from model T, Coprococcus
spp. (C. catus, C. comes and C. eutactus), Blautia spp. (B.
producta and B. obeum), Veillonella dispar and Lactobacillaceae
(L. fermentum and L. johnsonii) (Figures 4A, B). Similarly, the
enumerated recoveries of Lactobacillus spp. in model T showed a
1.2 log10 cfu/ml increase in response to trehalose instillation
(Supplementary Figure 1). However, the changes in microbiota
did not result in germination of C. difficile spores prior to addition
of clindamycin. This increase in certain bacterial populations were
mirrored by an increase in the number of Pfam domains associated
with trehalose metabolism in model T. Trehalase- (PF01204/
EC:3.2.1.28) and trehalose phosphatase-related (PF02358/
EC:3.1.3.12) Pfam domains increased 3.6- and 1.4-fold,
respectively, in abundance upon commencement of trehalose
dosing compared with pre-trehalose levels (Table 1). The
increased abundance of Pfam domains associated with trehalose
metabolism correlated with an increase abundance of those bacterial
species with known trehalose metabolising capabilities.Clindamycin Reduced the
Microbial Diversity
CDI induction is reliant onmicrobial disruption, typically through
antibiotic exposure. As we observed sugar-mediated microbiota
reconfiguration in our models, we sought to determine howA
B
C
FIGURE 2 | Taxonomic analysis of the faecal donors, pooled slurry and the steady state from the three individual models. Principal coordinate analysis of the five
donors and the faecal slurry based on 16S rRNA sequencing (A). Bacterial family abundance (%) found within the pooled faecal slurry used to initiate all models
(B) and at end of steady state period (experimental day 14) from the three models (G, T and S) (C).July 2021 | Volume 11 | Article 670935
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bioavailability of trehalose that could subsequently be utilised by
C. difficile. Clindamycin levels in vessel 1 peaked at 93.1, 142.5 and
127.1 mg/L, in models G, T and S, respectively. Upon clindamycin
instillation, bacterial diversity significantly decreased (p < 0.001)
from pre-clindamycin levels across all the models to a similar
extent (Figure 4 line graphs); however, by three weeks
after cessation of clindamycin instillation, bacterial diversity
had not recovered to pre-clindamycin levels. This decreased
diversity in all models was characterised by significantFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 7(p ≤ 0.01) reductions to Bifidobacteriaceae, Bacteroidaceae (B.
gallinarum and B. intestinalis), Lachnospiraceae, Alcaligenaceae,
Porphyromonadaceae and Veillonellaceae populations, either
during (intra-) or just after (four days post) clindamycin
(Figure 4 bar graphs). However, Enterobacteriaceae (specifically
E. coli and K. pneumoniae, as determined by MALDI-TOF
analysis) and Enterococcaceae increased in relative abundance
either during or just after antibiotic withdrawal, with an increase
in bacterial populations confirmed by direct culture using selective
agars (Enterobacteriaceae increased 2.4, 2.3, and 2.5 log10 cfu/ml;A
B
FIGURE 3 | Detection of glucose (A) and trehalose (B) in the gut models. Sugar concentrations from model T (blue lines), G (green lines), and S (red lines) were
detected by ion chromatography. Results are shown as mean ± S.D of three technical replicates. Sugar duration and clindamycin dosing are indicated by the top
green and blue arrows, respectively.July 2021 | Volume 11 | Article 670935
Buckley et al. Effect of Sugars on the MicrobiotaEnterococcus increased 1.8, 2.2, and 2.3 log10 cfu/ml, in models G,
S and T, respectively, during this time) (Supplementary Figure 1).
This pattern of clindamycin-induced microbial dysbiosis is
synonymous with induction of CDI in our in vitro gut model, as
previously seen (Chilton et al., 2014; Eyre et al., 2019).Trehalose Induced Microbiome Changes
Prevents Simulated CDI
We hypothesized that the differential pattern of clindamycin-
induced microbiota disruption, seen between the three models,
and the subsequent microbial recoveries would affect the
progression of simulated CDI. Prior to clindamycin instillation,
in both the saline supplemented model S (Figure 5A), and the
glucose supplemented model G (Figure 5B), C. difficile
populations remained in the form of spores from its addition
to the models on day 14. However, C. difficile germination andFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 8outgrowth was detected one-week post clindamycin (day 38)
with toxin detected from two days later until the end of the
experiment, which is consistent with simulated CDI. Similarly, in
the trehalose supplemented model, C. difficile spores remained
quiescent until day 38, where we detected germination and
limited outgrowth but, crucially, no toxin was detected
throughout the experiment and the C. difficile levels decreased
four days later to those consistent with the recovery of C. difficile
spores (Figure 5C). We have previously reported this phenotypic
observation in our gut model (Eyre et al., 2019). Thus, we further
investigated the comparative microbiota differences and
metabolic abundances on this day between models S/G and
model T related to C. difficile proliferation and onset of
simulated CDI.
Metagenomic analysis of the microbiota between models S/G
and model T on day 38 highlighted 25 significant differentially
abundant bacterial communities between model T (no simulated
CDI) and models S and G (induced simulated CDI) (Table 2).
Finegoldia magna, Blautia obeum, Faecalibacterium prausnitzii,
Dorea formicigenerans, Lactobacillus rhamnosus and Oscillospira
ruminantiumwere significantly (p< 0.001) more abundant inmodel
T compared with models G and S, whereas, Phascolarctobacterium
spp., Klebsiella spp. (K. pneumoniae and K. aerogenes), E. faecalis
and several Clostridium spp. [C. symbiosum, C. clostridioforme,
C. citroniae and Hungatella hathewayi (formally known as
C. hathewayi)] were significantly less abundant in modelTABLE 1 | Abundance of trehalose specific Pfam domains in model T.
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FIGURE 4 | Microbiota changes throughout the model timeline after supplementation with either trehalose (model T; A), glucose (model G; B) or saline (model S; C).
Upper line graphs represent diversity changes, as measured by Shannon Diversity Index, throughout the timeline. Results are shown as mean ± S.D of four technical
replicates analysed by 16S rRNA sequencing. Lower stacked bar charts represent the bacterial taxonomical abundance changes in each model over time. Results are
shown as mean of four technical replicates analysed by 16S rRNA sequencing.July 2021 | Volume 11 | Article 670935
Buckley et al. Effect of Sugars on the MicrobiotaT. The increased abundance of Lactobacillus spp. in model T at day
38 compared with models S and G, was confirmed by direct
enumeration, where Lactobacillus spp. levels in model T were 5.9
log10 cfu/ml, compared with 3.8 and 3.2 log10 cfu/ml for models S
and G, respectively (Supplementary Figure 1). Similarly, at day 38,
the recovery of Clostridium spp. and Enterobacteriaceaewere higher
in models S and G, compared with model T (Supplementary
Figure 1). Analysing the metagenome function showed that
components of the V/A-type ATPase were more abundant in
models G and S, a conserved ATPase found only in Enterococcus
spp (Murata et al., 2005). Additionally, the high levels ofClostridiumFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 9spp. (including former Clostridium species) found in models G and
S was reflected in the increased abundance of those genetic elements
involved in the sporulation cascade (spo genes).
Long-term supplementation of trehalose was associated with
enhanced recovery of the Ruminococcaceae family, particularly
the Oscillospira, Erysipelotrichaceae and Anaeroplasmataceae
genera, 3-weeks post-clindamycin (Figure 4A). Inversely,
Bifidobacteriaceae abundance in model T took longer to
recover than the other models, where abundance remained at
approximately 2% compared with 7.2-7.6% abundance observed
in the other models. This was reflected in the bacterial recoveriesFIGURE 5 | Recovery of C. difficile from model S, (S), model G, (G) and model T (T). Recovery of the total C. difficile populations (red lines) and the spore
populations (blue lines) from vessel 3 are shown for each model. Spore germination and outgrowth was determined by a divergence between the red and blue lines.
The detection of toxin is represented by orange arrows; there is no orange arrow for model T as no toxin was detected. Results expressed as mean ± SD from three
technical replicates. CD spores denotes when the C. difficile spores were inoculated into the model. Blue arrow denotes when clindamycin was instilled into the models.July 2021 | Volume 11 | Article 670935
Buckley et al. Effect of Sugars on the Microbiotawhere Bifidobacterium spp. levels recovered by days 13 and 9
(after clindamycin instillation) in models S and G, respectively,
and day 19 in model T.Functional Microbiome Changes
Associated With CDI
In order to identify the microbial pathways active during CDI
induction, a functional analysis of KEGG metabolic pathways was
performed between model T, supplemented with trehalose, and
models G and S, supplemented with glucose and saline
(Supplementary Table 3). Comparison of the functional
metabolic pathways between models was performed on day 38
(one-week post clindamycin), when CDI was detected inmodels G
and S but not in model T. Model T showed differences to the
metabolic landscape and cell surface components of the microbial
species present, in comparison tomodels G and S (Supplementary
Table 4). Whilst the abundance of genes involved in glucose/
gluconeogenesis and the pentose phosphate pathway were similar
across the models, other metabolic pathways that produced the
central metabolites glyceraldehyde-3 phosphate (G3P) and D-
glucose from different sugar sources, such lactose, galactose and
myo-inositol, were more abundant in models G and S, whereas
genes involved in trehalose metabolism were more abundant inFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 10model T (Figure 6A). Interestingly, several pathways to produce
amino acids (glutamine and glutamate) or amino acid precursors
(chorismate and D-ribose-1,5P) were abundant inmodels G and S.
Alongside the increased abundance of the intracellular stress
molecule guanosine pentaphosphate (ppGpp), this could indicate
a depleted pool of free amino acids (Supplementary Figure 2). In
contrast, we detected an increased abundance of genetic
components involved in the conversion of L-glutamine to the
short chain fatty acid, butyrate (Figure 6A).
Differential abundance analysis of the shotgun metagenome
sequences from these models suggests that the microbial species
could have distinctive cell surface arrangements. In all three
models, genetic elements associated with biofilm formation were
present; however, these genetic elements were different between
the models. Model T had increased abundance of genes involved
with curli biosynthesis, important in Enterobacteriaceae biofilm
formation, whereas, the genes involved in production of
extracellular matrix (PGA) were more abundant in models G
and S (Figure 6B). The presence of classical virulence factors
were also different; genetic elements associated with siderophore
production (yersiniabactin and bacitracin) and type 4 secretion
systems (T4SS) were more abundant in models G and S, whilst
genes involved in the production of polysaccharide capsule were
less abundant. Additionally, ABC transporter systems were
different between the models; sugar transport systems, for
ribose, lactose, arabinogalactan and cellobiose, were more
abundant in models G and S, whilst the general L-amino acid
transporter was more abundant in model T (Figure 6B).
In summary, the colonic microbiota remodelled to better
utilise the supplemented trehalose, and this was associated with
an increase in the abundance of trehalose-metabolising genes.
This lack of bioavailable trehalose negated the ability of a C.
difficile strain with enhanced trehalose metabolism to colonise
and cause fulfilment CDI, despite creating a growth niche with
clindamycin and continuous trehalose supplementation, unlike
glucose and saline supplementation.DISCUSSION
The consumption of trehalose has been proposed to contribute
to the emergence and virulence of CDI outbreaks, specifically in
those RTs harbouring genetic trehalose metabolism variants
(Collins et al., 2018a; Collins et al., 2018b). Some RT lineages,
such as RT027, have a mutated repressor, treR, gene, whilst
others, such as RT078, have acquired a putative ptsT transport
system, which gives them a competitive advantage during
pathogenesis (Collins et al., 2018b). However, we and others
have reported that these genetic variants are common in multiple
C. difficile lineages not associated with clinical outbreaks and
there was no association between trehalose metabolism variant
and clinical outcome (Eyre et al., 2019; Saund et al., 2020). Here
we describe the effects of trehalose supplementation on the
human microbiota and how the recovery of the microbiota can
affect simulated CDI, using a clinically reflective gut model. This
model has been used to successfully predict trial outcome atTABLE 2 | Differential abundance analysis of model T, compared to models G
and S, at day 38.
Population namea Log2 fold change
b
vs. Model G vs. Model S
s_Bacteroides uniformis -15.24 -15.14
s_Faecalibacterium prausnitzii -15.07 -14.97
s_Finegoldia magna -14.92 -14.82
s_Blautia obeum -14.81 -14.71
s_Dorea formicigenerans -14.57 -14.47
s_Lactobacillus rhamnosus -12.35 -12.25
s_Oscillibacter ruminantium -2.61 -19.61
s_Hungatella hathewayi 18.22 16.8
s_Clostridium symbiosum 17.12 18.08
s_Klebsiella aerogenes 17.05 16.72
s_Blautia producta 15.51 16.06
s_Clostridium clostridioforme 15.30 16.43
s_Enterococcus faecalis 3.4 3.59
s_Klebsiella pneumoniae 3.18 2.27










f_Peptoniphilaceae -12.44 -12.34aTaxonomic level of microbial populations from whole genome sequencing data.
s_ species, g_ genus or f_ family.
bLog2 fold change compared with model T, i.e. a positive number (red) indicates microbial
population was significantly (FDR p ≤ 0.01) less abundant in model T compared with
models G and S, whilst a negative number (green) indicates microbial population was
significantly (FDR p ≤ 0.01) more abundant in model T.July 2021 | Volume 11 | Article 670935
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development. However, due to the limited number of
biological replicates (n=2), our conclusions are presented as
preliminary findings. Numerous reports have highlighted key
microbiota differences between humans and mice (Ley et al.,
2005; Nguyen et al., 2015), which is potentially important given
the contribution of the microbiota towards colonisation
resistance against CDI. Indeed, mice bred in captivity, on the
same diet, have a similar microbiota (Hufeldt et al., 2010), which
is far removed from the heterogeneity displayed within in a
human population, and could result in different clinical
outcomes (Selber-hnativ et al., 2017). The major human
microbial communities present in the donor faeces were
represented in the faecal slurry used to seed each model, and
we subsequently recaptured these communities in each of our
human ‘gut models’. Three independent models were run in
parallel, supplemented with either trehalose, glucose or saline. As
trehalose can be metabolised into two glucose molecules, this
experimental approach was used to delineate the effects of
trehalose rather than its breakdown product.
Trehalose supplementation immediately increased the
trehalose concentration in vessels 1 and 2; however, despite
continued trehalose supplementation, the levels decreased to
undetectable levels, suggesting microbial trehalose metabolism.
This drop in trehalose concentration was specifically associated
with an increased abundance of trehalose metabolising Pfam
domains and a corresponding remodelling of the microbiota toFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 11include higher abundancies of B. uniformis, B. producta and V.
dispar. Many strains of these bacterial species are known to
harbour treA-like genes, a trehalose-6-phosphatase that
metabolises trehalose into glucose and glucose-6-phosphate
monomers (Rogosa, 1964; Whatmore et al., 1990; Liu et al.,
2008). Trehalose metabolism appears not to be restricted to these
bacterial species, indeed, the UniProt protein sequence
repository suggests trehalose metabolising genes are ubiquitous
amongst bacterial species (Bateman et al., 2017). Further
evidence of the role of the intestinal microbiota to metabolise
trehalose is shown during clindamycin exposure. Clindamycin is
a broad-spectrum antibiotic that has previously been shown to
induce CDI in our gut model (Chilton et al., 2014). Clindamycin
instillation decreased the microbial diversity in all models,
causing simulated intestinal dysbiosis, which correlated with
increased bioavailability of trehalose. It would be interesting to
see if this effect is replicated using other antibiotics associated
with induction of CDI. The levels of trehalose returned to
undetectable levels in vessels 2 and 3 prior to completion of
the clindamycin regimen; these vessels simulate the medial and
distal colon, which is most conducive for CDI (Freeman et al.,
2003). We used a highly sensitive method to quantify trehalose/
glucose concentrations, with a limit of detection at 0.5µM.
Collins et al. reported C. difficile trehalose metabolism variants
that could utilise 50µM-25mM concentrations of trehalose more
efficiently, compared with wildtype trehalose metabolism
variants (Collins et al., 2018a). We hypothesised that, althoughA B
FIGURE 6 | Differential abundance analysis (fold-change) of metabolic pathways in model T compared to models G (solid bars) and S (hatched bars) at day 38,
based on metagenomics analysis. Abundance bars highlight the KEGG metabolic pathways (A) or KEGG cell surface components (B) that are significantly (p=<0.05)
more abundant (>-1.5 fold-change) or less abundant (>1.5 fold-change) in model T. Pathways or components were only included where 80% of the genetic
elements in that pathway/component showed an increased or decreased abundance from technical replicates of model T compared to both models G and S
(Supplementary Table 4).July 2021 | Volume 11 | Article 670935
Buckley et al. Effect of Sugars on the MicrobiotaC. difficile trehalose metabolism variants could have a
competitive advantage over wildtype isolates, this competitive
advantage is diminished in the presence of the human
microbiota, as the intestinal microbiota is an important source
of trehalose metabolism, potentially reducing the bioavailability
of trehalose during CDI. However, the competitiveness of the
human microbiota against C. difficile with respect to trehalose
utilisation requires further study to determine mechanisms of
competition under in vivo conditions. Further evidence for this is
shown using degradation-resistant trehalose analogues, such as
lactotrehalose, which show enhanced faecal bioavailability and,
additionally, does not induce CDI in a mouse model (Zhang and
DeBosch, 2020). The Ribotype 027 strain used in our studies
possesses a treR mutation. It would be interesting to determine
the competitiveness of a strain harbouring a putative ptsT
transport system, which could provide a competitive trehalose
metabolic advantage over the microbiota (Collins et al., 2018b).
Instillation of clindamycin did result in induction of
simulated CDI in models supplemented with either glucose or
saline; however, trehalose supplementation did not result in
simulated CDI [(Eyre et al., 2019) and Figure 5]. Differential
taxonomic abundance between model T and models G/S
identified bacterial species that were either more (n=7) or less
(n=8) abundant in model T; although these data are from one
independent biological repeat of each condition. Of the bacterial
species associated with protection against CDI, B. uniformis was
the dominant Bacteroides species identified in model T (3% of
total reads) and is capable of metabolising trehalose. Through
metabolite cross-feeding, B. uniformis can support the growth of
F. prausnitzii (Chung et al., 2016), and vice versa, which
enhances the growth of both species. F. prausnitzii is known to
produce butyrate and formate, which have been shown to reduce
inflammation during infection (Fachi et al., 2019), but increased
levels of F. prausnitzii were associated with recovery from CDI in
patients and in vivomodels (Khanna et al., 2016; Roychowdhury
et al., 2018). Strains of B. obeum can also utilise trehalose, and
crucially, have been shown to reduce virulence gene expression,
through quorum sensing, during Vibrio cholerae infection (Hsiao
et al., 2014); toxin synthesis by C. difficile can be regulated by
different quorum sensing (Lee and Song, 2005; Darkoh et al.,
2015). The metabolic interconnectivity between these microbial
species could represent a consortium that competes for nutrients
utilised by C. difficile after spore germination (as hypothesised in
Supplementary Figure 3). Furthermore, the increased
abundance of these bacterial species associated with CDI
prevention in model T are less abundant in the faeces from
CDI patients and have been attributed with protective effects in
putative microbiome restoratives (Reeves et al., 2011; Petrof
et al., 2013; Milani et al., 2016). Moreover, carbohydrate-
induced microbiota outgrowth, and subsequent metabolic
products, were associated with a decrease in C. difficile fitness
(Hryckowian et al., 2018), similar to our in vitro findings. In our
study we used the microbiota from healthy donors above the age
of 59 as this age group has the highest risk of developing CDI.
However, we know that microbiome composition is affected by
age (Pasolli 2019), thus it would be interesting to determine ifFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 12donors from other age groups have a differing ability to
metabolise trehalose. Aside from acting as a potential carbon
source, intracellular trehalose has unique properties that could
protect cells from the effects of antibiotics, such as a membrane
osmoprotectant and a protein stabilising molecule (Elbein et al.,
2003; Jain and Roy, 2009).
Interestingly, 4 different Clostridium spp. were associated
with CDI induction in model’s G/S. A similar observation was
noted by Khanna et al. (2016) and Daquigan et al. (2017), where
several Clostridium spp. were associated with increased C.
difficile abundance in CDI and recurrent CDI patients.
Additionally, Girinathan et al. showed the presence of
Clostridium sardiniense enhanced CDI in an in vivo model of
disease (Girinathan et al., 2020). Conversely, the authors
observed that C. bifermentans, an amino acid fermenter,
prevented CDI-induced death in an animal model of infection.
The bioavailability of amino acids play a crucial role in C. difficile
pathogenesis. Glycine is a potent germinator for C. difficile
spores, and C. difficile utilises amino acids, particularly
isoleucine and proline, during in vitro and in vivo growth as
both a carbon source and an energy source, via Stickland
reactions (Bouillaut et al., 2013; Hofmann et al., 2018;
Battaglioli et al., 2018; Robinson et al., 2019). Microorganisms
that compete for bioavailable amino acids, such as C.
bifermentans, could prevent the rapid proliferation of C.
difficile during CDI (Girinathan et al., 2020). Indeed, the CDI-
linked functional profile of the microbiota favoured the
production of amino acids (or amino acid precursors) from
sugars, potentially due to a reduced pool of bioavailable amino
acids after being used by C. difficile during pathogen expansion.
This was mirrored in the functions of the cell surface ABC
transporters where there was an increased abundance of sugar
transporters in models G and S, potentially associated with C.
difficile proliferation niche. The identified metabolic pathways
and putative metabolic products associated with CDI induction
in our gut models, namely G3P/D-ribose-5P/succinyl-CoA/
inosine, have been shown to be utilised by C. difficile during in
vivo growth in a murine model of infection (Jenior et al., 2017)
and as CDI-associated metabolites in cohorts of CDI patients
(Robinson et al., 2019). Other CDI-associated metabolites, such
as ethanolamine and succinate, identified in this study have been
confirmed as an important nutrient source (Ferreyra et al., 2014;
McDonald et al., 2018; Nawrocki et al., 2018).
By studying the effect of trehalose at a systems level, we
outline plasticity of the human microbiome to adapt to utilise
this carbon source, providing competition with C. difficile. The
absence of enhanced CDI associated with trehalose in this model
system, and the mechanisms explained, could help explain why
clinical outcome was not associated with genetic markers for
enhanced trehalose metabolism. Contrary to enhancing CDI,
trehalose utilisation was preliminary linked with a consortium of
cross-feeding microbial species that may be antagonistic to the
growth of C. difficile, which can form the rationale for the basis of
microbial therapies used for treating CDI infections
(Supplementary Figure 3). Further in vitro and in vivo studies
are required to confirm these preliminary data.July 2021 | Volume 11 | Article 670935
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